文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Recent Development of LDL-Based Nanoparticles for Cancer Therapy.

作者信息

He Binghong, Yang Qiong

机构信息

Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China.

出版信息

Pharmaceuticals (Basel). 2022 Dec 23;16(1):18. doi: 10.3390/ph16010018.


DOI:10.3390/ph16010018
PMID:36678515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9863478/
Abstract

Low-density lipoprotein (LDL), a natural lipoprotein transporting cholesterol in the circulatory system, has been a possible drug carrier for targeted delivery. LDL can bind to the LDL receptor (LDLR) with its outside apolipoprotein B-100 and then enter the cell via LDLR-mediated endocytosis. This targeting function inspires researchers to modify LDL to deliver different therapeutic drugs. Drugs can be loaded in the surficial phospholipids, hydrophobic core, or apolipoprotein for the structure of LDL. In addition, LDL-like synthetic nanoparticles carrying therapeutic drugs are also under investigation for the scarcity of natural LDL. In addition to being a carrier, LDL can also be a targeting molecule, decorated to the surface of synthetic nanoparticles loaded with cytotoxic compounds. This review summarizes the properties of LDL and the different kinds of LDL-based delivery nanoparticles, their loading strategies, and the achievements of the recent anti-tumor advancement.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/95980c3f4979/pharmaceuticals-16-00018-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/c56911456425/pharmaceuticals-16-00018-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/5c830982c079/pharmaceuticals-16-00018-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/29146484cc84/pharmaceuticals-16-00018-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/c5ca0609ce03/pharmaceuticals-16-00018-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/95980c3f4979/pharmaceuticals-16-00018-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/c56911456425/pharmaceuticals-16-00018-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/5c830982c079/pharmaceuticals-16-00018-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/29146484cc84/pharmaceuticals-16-00018-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/c5ca0609ce03/pharmaceuticals-16-00018-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7823/9863478/95980c3f4979/pharmaceuticals-16-00018-g005.jpg

相似文献

[1]
Recent Development of LDL-Based Nanoparticles for Cancer Therapy.

Pharmaceuticals (Basel). 2022-12-23

[2]
Low-density lipoprotein-decorated and Adriamycin-loaded silica nanoparticles for tumor-targeted chemotherapy of colorectal cancer.

Adv Clin Exp Med. 2019-4

[3]
Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents.

Mol Imaging. 2008

[4]
Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs.

Saudi Pharm J. 2014-12

[5]
Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.

Acta Biomater. 2019-6-28

[6]
Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential.

Drug Deliv. 2021-12

[7]
Cancer targeted drug delivery using active low-density lipoprotein nanoparticles encapsulated pyrimidines heterocyclic anticancer agents as microtubule inhibitors.

Drug Deliv. 2022-12

[8]
Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100.

J Biol Chem. 1995-8-18

[9]
Low-density lipoprotein decorated and indocyanine green loaded silica nanoparticles for tumor-targeted photothermal therapy of breast cancer.

Pharm Dev Technol. 2019-12-10

[10]
Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.

Life Sci. 2019-10-31

引用本文的文献

[1]
Functionalized Boron Carbide Nanoparticles as Active Boron Delivery Agents Dedicated to Boron Neutron Capture Therapy.

Int J Nanomedicine. 2025-5-24

[2]
Application of Nanomaterials in Early Imaging and Advanced Treatment of Atherosclerosis.

Chem Biomed Imaging. 2025-1-21

[3]
Anti-inflammatory Therapies for Ischemic Heart Disease.

Curr Cardiol Rep. 2025-2-19

[4]
Docosahexaenoic acid-loaded nanoparticles: A state-of-the-art of preparation methods, characterization, functionality, and therapeutic applications.

Heliyon. 2024-5-9

本文引用的文献

[1]
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.

Lancet Oncol. 2022-9

[2]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[3]
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

J Clin Oncol. 2021-12-10

[4]
Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.

Acc Chem Res. 2020-10-20

[5]
Low-density lipoprotein decorated and indocyanine green loaded silica nanoparticles for tumor-targeted photothermal therapy of breast cancer.

Pharm Dev Technol. 2019-12-10

[6]
Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.

Int J Nanomedicine. 2019-9-11

[7]
Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.

Life Sci. 2019-10-31

[8]
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

JAMA Oncol. 2020-3-1

[9]
Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.

Acta Biomater. 2019-6-28

[10]
Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.

Drug Deliv. 2018-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索